Tarsus Pharmaceuticals, Inc.(TARS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TARS Tarsus Pharmaceuticals, Inc.

Post-Mkt 08-27 16:30:54 EDT

71.92

+1.27

+1.80%

盘后71.92

+0.000.00%

16:10 EDT

High72.15	Low69.47	Vol565.94K
Open70.07	D1 Closing70.65	Amplitude3.79%
Mkt Cap3.16B	Tradable Cap2.35B	Total Shares43.88M
T/O40.51M	T/O Rate1.73%	Tradable Shares32.68M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TARS","market":"US","secType":"STK","nameCN":"Tarsus Pharmaceuticals, Inc.","latestPrice":71.92,"timestamp":1787860800000,"preClose":70.65,"halted":0,"volume":565944,"hourTrading":{"tag":"盘后","latestPrice":71.92,"preClose":71.92,"latestTime":"16:10 EDT","volume":13286,"amount":955529.12,"timestamp":1787861405576,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.017975937721160594,"floatShares":32679899,"shares":43882996,"eps":-1.082408,"marketStatus":"Post-Mkt","change":1.27,"latestTime":"08-27 16:30:54 EDT","open":70.07,"high":72.145,"low":69.465,"amount":40505170,"amplitude":0.037933,"askPrice":73.34,"askSize":27,"bidPrice":70.48,"bidSize":28,"shortable":3,"etf":0,"ttmEps":-1.082408,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787875200000},"marketStatusCode":4,"adr":0,"listingDate":1602820800000,"exchange":"NASDAQ","adjPreClose":70.65,"preHourTrading":{"tag":"盘前","latestPrice":70.7,"preClose":70.65,"latestTime":"09:18 EDT","volume":251,"amount":17809.73763,"timestamp":1787836685575,"change":0.05,"changeRate":0.000708,"amplitude":0.018117},"postHourTrading":{"tag":"盘后","latestPrice":71.92,"preClose":71.92,"latestTime":"16:10 EDT","volume":13286,"amount":955529.12,"timestamp":1787861405576,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.033351,"impliedVol":0.7685,"impliedVolPercentile":0.9522},"requestUrl":"/m/hq/s/TARS/wiki","defaultTab":"wiki","newsList":[{"id":"2660545237","title":"Tarsus Pharmaceuticals (TARS) Shares Just Moved, What Is Behind The Attention?","url":"https://stock-news.laohu8.com/highlight/detail?id=2660545237","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660545237?lang=en_us&edition=fundamental","pubTime":"2026-08-18 13:21","pubTimestamp":1787030482,"startTime":"0","endTime":"0","summary":"Why Tarsus Pharmaceuticals stock is in focus after Q2 2026\nTarsus Pharmaceuticals (TARS) is back on investors radar after its Q2 2026 earnings report showed higher revenue, a smaller net loss, and a higher full year sales outlook for XDEMVY.\nSee our latest analysis for Tarsus Pharmaceuticals.\nTarsus Pharmaceuticals shares have reacted positively to the Q2 2026 update, with a 17.99% 1 month share price return and a 15.21% 3 month share price return, while the year to date share price is still...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tars/tarsus-pharmaceuticals/news/tarsus-pharmaceuticals-tars-shares-just-moved-what-is-behind","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tars/tarsus-pharmaceuticals/news/tarsus-pharmaceuticals-tars-shares-just-moved-what-is-behind","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TARS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658189906","title":"Tarsus Pharmaceuticals Price Target Raised to $100.00/Share from $97.00 by Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2658189906","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658189906?lang=en_us&edition=fundamental","pubTime":"2026-08-12 23:26","pubTimestamp":1786548360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TARS/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARS","OPY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658909977","title":"Oppenheimer Adjusts PT on Tarsus Pharmaceuticals to $100 From $97, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2658909977","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658909977?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:33","pubTimestamp":1786538039,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals (TARS) has an average rating of buy and mean price target of $95.57, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ma","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TARS","OPY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658867210","title":"Why Tarsus Pharmaceuticals (TARS) Is Up 9.7% After Raising XDEMVY 2026 Sales Guidance And Acquiring Alkeus","url":"https://stock-news.laohu8.com/highlight/detail?id=2658867210","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658867210?lang=en_us&edition=fundamental","pubTime":"2026-08-09 16:35","pubTimestamp":1786264551,"startTime":"0","endTime":"0","summary":"In early August 2026, Tarsus Pharmaceuticals reported second-quarter revenue of US$173.91 million and a net loss of US$18.55 million, while also raising full-year 2026 XDEMVY net product sales guidance to US$685 million–US$705 million.\nThe earnings update highlighted strong XDEMVY uptake, with more than 700,000 patients treated since launch and an acquisition of Alkeus Pharmaceuticals to broaden Tarsus’ ophthalmology pipeline.\nWe’ll now examine how this stronger XDEMVY sales outlook and...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tars/tarsus-pharmaceuticals/news/why-tarsus-pharmaceuticals-tars-is-up-97-after-raising-xdemv","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tars/tarsus-pharmaceuticals/news/why-tarsus-pharmaceuticals-tars-is-up-97-after-raising-xdemv","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TARS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657364252","title":"Mizuho Adjusts Tarsus Pharmaceuticals PT to $100 From $98, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2657364252","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657364252?lang=en_us&edition=fundamental","pubTime":"2026-08-07 22:45","pubTimestamp":1786113957,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals (TARS) has an average rating of buy and mean price target of $94.22, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ma","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TARS","MFG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657628026","title":"Tarsus Pharmaceuticals Balances XDEMVY Surge With Retina Bet","url":"https://stock-news.laohu8.com/highlight/detail?id=2657628026","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657628026?lang=en_us&edition=fundamental","pubTime":"2026-08-07 08:13","pubTimestamp":1786061623,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals, Inc. (($TARS)) has held its Q2 earnings call. Read on for the main highlights of the call. Tarsus Pharmaceuticals’ latest e...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tarsus-pharmaceuticals-balances-xdemvy-surge-with-retina-bet?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tarsus-pharmaceuticals-balances-xdemvy-surge-with-retina-bet?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FEBU","VOTE","GXDW","TARS","RGLO","JOYT","VGFPF","PMDE","DECU","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657666653","title":"Tarsus Pharmaceuticals Q2 EPS $(0.43) Misses $(0.20) Estimate, Sales $173.912M Beat $169.677M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657666653","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657666653?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:41","pubTimestamp":1786052510,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.20) by 115 percent. This is a 10.42 percent increase over losses of $(0.48) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61026146/tarsus-pharmaceuticals-q2-eps-0-43-misses-0-20-estimate-sales-173-912m-beat-169-677m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Tarsus Pharmaceuticals Q2 EPS $(0.43) Misses $(0.20) Estimate, Sales $173.912M Beat $169.677M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657668635","title":"Verrica Pharma Reports Wider-than-Expected Q2 Adj Loss Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2657668635","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657668635?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:29","pubTimestamp":1786048170,"startTime":"0","endTime":"0","summary":"Verrica Pharma reports wider-than-expected Q2 adj loss per shareOverviewUS dermatology therapeutics firm's Q2 revenue declined yr/yr as prior-year included one-time milestoneAdjusted loss per share fo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431FK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRCA","TARS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657653258","title":"Tarsus Pharmaceuticals, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657653258","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657653258?lang=en_us&edition=fundamental","pubTime":"2026-08-06 23:40","pubTimestamp":1786030838,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings SummaryTarsus Pharmaceuticals, Inc.TARS.OQreported a quarterly adjusted loss of 49 cents per share for the quarter","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4432MU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TARS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657639424","title":"Tarsus Pharmaceuticals announces $125M private placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2657639424","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657639424?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:10","pubTimestamp":1786018251,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals (TARS) announced that it has entered into a securities purchase agreement with certain qualified institutional buyers and ac...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tarsus-pharmaceuticals-announces-125m-private-placement-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tarsus-pharmaceuticals-announces-125m-private-placement-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TARS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657306635","title":"Tarsus Pharmaceuticals Q2 Sales Beat Estimates, Lifts 2026 Xdemvy Sales Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2657306635","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657306635?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:36","pubTimestamp":1786016209,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals Q2 sales beat estimates, lifts 2026 XDEMVY sales outlookOverviewUS eye care drugmaker's Q2 product sales rose over 69% yr/yr, beating analyst expectationsPending acquisition of ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430I5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RXST","SGHT","BK4539","BK4082","BK4198","BK4007","OCUL","TARS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638725","title":"Tarsus to Buy Alkeus in Deal Worth About $450 Million Upfront","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638725","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638725?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:14","pubTimestamp":1786014895,"startTime":"0","endTime":"0","summary":"Tarsus to buy Alkeus in deal worth about $450 million upfrontTarsus agreed to buy privately held Alkeus Pharmaceuticals, adding Phase 3 Stargardt disease candidate gildeuretinol (ALK-001) to its eye-c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL6xCczb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638712","title":"Tarsus Prices USD 125 Million PIPE at USD 56 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638712","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638712?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:14","pubTimestamp":1786014870,"startTime":"0","endTime":"0","summary":"Tarsus prices USD 125 million PIPE at USD 56 per shareTarsus Pharmaceuticals priced an oversubscribed $125 million PIPE, selling 2,098,519 common shares at USD 56 per share.The deal also includes pre-","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDLc7JQ4v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1201861165.SGD","BK4585","LU2129689514.USD","UYG","LU0306806265.USD","LU0964806797.USD","IYG","FNCL","LU0868494617.USD","LU1883839398.USD","LU0070302665.USD","IYF","LU1363072403.SGD","BAC","FTXO","LU2129689431.USD","IE00BBT3K403.USD","VFH","BK4588","LU0320765646.SGD","LU0161305163.EUR","LU1069347547.HKD","LU2129689605.HKD","BK4534","LU0208291251.USD","LU1280957306.USD","LU0417517546.SGD","XLF","LU0321505439.SGD","LU1880398554.USD","BARC.UK","LU0345777147.USD","LU1291159041.SGD","LU2133065610.SGD","IE0001KFT4U8.USD","BK4504","LU1015430645.USD","LU0987226296.USD","BK5152","KBWB","LU2646069778.SGD","TARS","LU0053666078.USD","TFNS","LU0052756011.USD","LU1718418525.SGD","LU0047473722.SGD","LU1035777561.USD","LU0997586606.USD","LU1078025761.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638224","title":"Tarsus Q2 FY26 Net Loss Narrows 8.77% to $18.55 Million; Net Product Sales Rise More than 69% to $173.91 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638224","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638224?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:12","pubTimestamp":1786014728,"startTime":"0","endTime":"0","summary":"Tarsus Q2 FY26 net loss narrows 8.77% to $18.55 million; net product sales rise more than 69% to $173.91 millionTarsus posted Q2 2026 net sales of USD 173.9 million, up more than 69% year over year.Ne","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL8bXdYt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TARS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657388096","title":"Tarsus Pharmaceuticals Q2 EPS USD -0.43","url":"https://stock-news.laohu8.com/highlight/detail?id=2657388096","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657388096?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:03","pubTimestamp":1786014181,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLX0CPQ7W:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TARS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638874","title":"Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638874","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638874?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:03","pubTimestamp":1786014180,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUACBWZZB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TARS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657680059","title":"Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2657680059","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657680059?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:02","pubTimestamp":1786014120,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUA4TMMVD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TARS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657756680","title":"Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2657756680","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657756680?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:01","pubTimestamp":1786014060,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUA1GD1JR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TARS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657680758","title":"Tarsus Pharmaceuticals, - up to $350 Mln in Milestone Payments upon Regulatory Approval and First Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2657680758","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657680758?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:01","pubTimestamp":1786014060,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUA1GD1JR:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TARS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657168073","title":"Tarsus Pharmaceuticals, - Deal Includes $450 Mln Upfront, $270 Mln Cash, $180 Mln in Tarsus Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2657168073","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657168073?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:01","pubTimestamp":1786014060,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUA1GD1JR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TARS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tarsusrx.com","stockEarnings":[{"period":"1week","weight":-0.038},{"period":"1month","weight":0.1751},{"period":"3month","weight":0.1866},{"period":"6month","weight":-0.0645},{"period":"1year","weight":0.2005},{"period":"ytd","weight":-0.1372}],"compareEarnings":[{"period":"1week","weight":-0.0039},{"period":"1month","weight":0.0365},{"period":"3month","weight":0.0152},{"period":"6month","weight":0.1168},{"period":"1year","weight":0.1874},{"period":"ytd","weight":0.1234}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tarsus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.002743},{"month":2,"riseRate":0.333333,"avgChangeRate":0.037237},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.051747},{"month":4,"riseRate":0.5,"avgChangeRate":0.00177},{"month":5,"riseRate":0.5,"avgChangeRate":-0.038644},{"month":6,"riseRate":0.5,"avgChangeRate":-0.027034},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.030731},{"month":8,"riseRate":0.833333,"avgChangeRate":0.1359},{"month":9,"riseRate":0.8,"avgChangeRate":0.033781},{"month":10,"riseRate":0.8,"avgChangeRate":0.135195},{"month":11,"riseRate":0.666667,"avgChangeRate":0.092511},{"month":12,"riseRate":0.666667,"avgChangeRate":0.122111}],"exchange":"NASDAQ","name":"Tarsus Pharmaceuticals, Inc.","nameEN":"Tarsus Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tarsus Pharmaceuticals, Inc.(TARS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tarsus Pharmaceuticals, Inc.(TARS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tarsus Pharmaceuticals, Inc.,TARS,Tarsus Pharmaceuticals, Inc.股票,Tarsus Pharmaceuticals, Inc.股票老虎,Tarsus Pharmaceuticals, Inc.股票老虎国际,Tarsus Pharmaceuticals, Inc.行情,Tarsus Pharmaceuticals, Inc.股票行情,Tarsus Pharmaceuticals, Inc.股价,Tarsus Pharmaceuticals, Inc.股市,Tarsus Pharmaceuticals, Inc.股票价格,Tarsus Pharmaceuticals, Inc.股票交易,Tarsus Pharmaceuticals, Inc.股票购买,Tarsus Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tarsus Pharmaceuticals, Inc.(TARS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tarsus Pharmaceuticals, Inc.(TARS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction